JNJ-61186372 is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. JNJ-61186372 was created under a collaboration between Genmab and Janssen Biotech, Inc. using Genmab’s DuoBody® technology. The two antibodies used to create JNJ-61186372 were both created by Genmab. 

Clinical studies
JNJ-61186372 is being investigated in Phase II clinical studies to treat non-small cell lung cancer (NSCLC). For more information, visit